Total Payments
$3,851
2024 Payments
$320.79
Companies
16
Transactions
158
Medicare Patients
1,117
Medicare Billing
$111,073
Payment Breakdown by Category
Food & Beverage$3,518 (91.3%)
Education$333.65 (8.7%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $3,518 | 153 | 91.3% |
| Education | $333.65 | 5 | 8.7% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| La Jolla Pharmaceutical Company | $884.78 | 11 | $0 (2023) |
| Astellas Pharma US Inc | $765.56 | 24 | $0 (2024) |
| Gilead Sciences, Inc. | $467.92 | 25 | $0 (2023) |
| ViiV Healthcare Company | $394.96 | 22 | $0 (2022) |
| Paratek Pharmaceuticals, Inc. | $364.27 | 20 | $0 (2024) |
| Melinta Therapeutics, LLC | $295.48 | 17 | $0 (2024) |
| Merck Sharp & Dohme LLC | $188.79 | 10 | $0 (2024) |
| ABBVIE INC. | $182.45 | 11 | $0 (2023) |
| Theratechnologies Inc. | $58.16 | 3 | $0 (2023) |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | $57.15 | 3 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $320.79 | 14 | Astellas Pharma US Inc ($160.25) |
| 2023 | $677.65 | 29 | Astellas Pharma US Inc ($230.22) |
| 2022 | $980.79 | 50 | ViiV Healthcare Company ($271.63) |
| 2021 | $1,872 | 65 | La Jolla Pharmaceutical Company ($787.45) |
All Payment Transactions
158 individual payment records from CMS Open Payments — Page 1 of 7
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/19/2024 | Melinta Therapeutics, LLC | Rezzayo (Drug), Kimyrsa | Food and Beverage | In-kind items and services | $25.72 | General |
| Category: ANTIFUNGALS | ||||||
| 11/13/2024 | Astellas Pharma US Inc | Cresemba (Drug) | Food and Beverage | In-kind items and services | $23.17 | General |
| Category: Infectious Diseases | ||||||
| 09/10/2024 | Astellas Pharma US Inc | Cresemba (Drug) | Food and Beverage | In-kind items and services | $23.33 | General |
| Category: Infectious Diseases | ||||||
| 08/08/2024 | Melinta Therapeutics, LLC | Rezzayo (Drug), Kimyrsa | Food and Beverage | In-kind items and services | $23.30 | General |
| Category: ANTIFUNGALS | ||||||
| 07/23/2024 | Melinta Therapeutics, LLC | Rezzayo (Drug), Kimyrsa | Food and Beverage | In-kind items and services | $23.27 | General |
| Category: ANTIFUNGALS | ||||||
| 07/10/2024 | Astellas Pharma US Inc | Cresemba (Drug) | Food and Beverage | In-kind items and services | $20.79 | General |
| Category: Infectious Diseases | ||||||
| 05/23/2024 | Paratek Pharmaceuticals, Inc. | NUZYRA (Drug) | Food and Beverage | In-kind items and services | $20.64 | General |
| Category: ANTIBIOTIC | ||||||
| 05/08/2024 | Astellas Pharma US Inc | Cresemba (Drug) | Food and Beverage | In-kind items and services | $34.72 | General |
| Category: Infectious Diseases | ||||||
| 05/08/2024 | Melinta Therapeutics, LLC | Rezzayo (Drug), Kimyrsa | Food and Beverage | In-kind items and services | $15.23 | General |
| Category: ANTIFUNGALS | ||||||
| 04/03/2024 | Melinta Therapeutics, LLC | Rezzayo (Drug), Kimyrsa | Food and Beverage | In-kind items and services | $17.62 | General |
| Category: ANTIFUNGALS | ||||||
| 03/05/2024 | Astellas Pharma US Inc | Cresemba (Drug) | Food and Beverage | In-kind items and services | $26.37 | General |
| Category: Infectious Diseases | ||||||
| 02/22/2024 | Merck Sharp & Dohme LLC | DIFICID (Drug), RECARBRIO, ZERBAXA | Food and Beverage | In-kind items and services | $20.32 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 02/21/2024 | Melinta Therapeutics, LLC | Rezzayo (Drug), Kimyrsa | Food and Beverage | In-kind items and services | $14.44 | General |
| Category: ANTIFUNGALS | ||||||
| 01/10/2024 | Astellas Pharma US Inc | Cresemba (Drug) | Food and Beverage | In-kind items and services | $31.87 | General |
| Category: Infectious Diseases | ||||||
| 12/20/2023 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $32.15 | General |
| 12/19/2023 | Gilead Sciences, Inc. | Veklury (Drug) | Food and Beverage | In-kind items and services | $30.56 | General |
| Category: COVID-19 | ||||||
| 12/13/2023 | Melinta Therapeutics, LLC | Rezzayo (Drug), Kimyrsa | Food and Beverage | In-kind items and services | $13.31 | General |
| Category: ANTIFUNGALS | ||||||
| 10/24/2023 | Astellas Pharma US Inc | Cresemba (Drug) | Food and Beverage | In-kind items and services | $31.19 | General |
| Category: Infectious Diseases | ||||||
| 09/26/2023 | Gilead Sciences, Inc. | Veklury (Drug) | Food and Beverage | In-kind items and services | $21.67 | General |
| Category: COVID-19 | ||||||
| 08/30/2023 | Takeda Pharmaceuticals U.S.A., Inc. | GATTEX (Drug) | Food and Beverage | In-kind items and services | $13.46 | General |
| Category: INTERNAL MEDICINE | ||||||
| 08/29/2023 | La Jolla Pharmaceutical Company | XERAVA (Drug) | Food and Beverage | In-kind items and services | $16.24 | General |
| Category: TETRACYCLINE CLASS ANTIBACTERIAL | ||||||
| 08/28/2023 | Theratechnologies Inc. | EGRIFTA (Drug), TROGARZO | Food and Beverage | In-kind items and services | $30.33 | General |
| Category: HIV | ||||||
| 08/10/2023 | Astellas Pharma US Inc | Cresemba (Drug) | Food and Beverage | In-kind items and services | $25.27 | General |
| Category: Infectious Diseases | ||||||
| 08/01/2023 | Merck Sharp & Dohme LLC | PIFELTRO (Drug), DELSTRIGO, DIFICID | Food and Beverage | In-kind items and services | $23.00 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 06/22/2023 | Janssen Biotech, Inc. | SYMTUZA (Drug) | Food and Beverage | In-kind items and services | $14.41 | General |
| Category: Infectious Diseases & Vaccines | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 6 | 620 | 1,228 | $301,508 | $67,011 |
| 2022 | 5 | 325 | 532 | $144,913 | $29,080 |
| 2021 | 2 | 72 | 119 | $33,280 | $6,534 |
| 2020 | 3 | 100 | 154 | $42,980 | $8,447 |
Total Patients
1,117
Total Services
2,033
Medicare Billing
$111,073
Procedure Codes
16
All Medicare Procedures & Services
16 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 306 | 784 | $161,615 | $39,235 | 24.3% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 87 | 92 | $59,832 | $8,474 | 14.2% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 47 | 99 | $27,327 | $7,323 | 26.8% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 83 | 88 | $33,196 | $6,420 | 19.3% |
| 99231 | Subsequent hospital care with straightforward or low level of medical decision making, per day, if using time, at least 25 minutes | Facility | 2023 | 78 | 146 | $14,617 | $4,568 | 31.3% |
| 99221 | Initial hospital care with straightforward or low level of medical decision making, per day, if using time, at least 40 minutes | Facility | 2023 | 19 | 19 | $4,921 | $991.23 | 20.1% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 162 | 320 | $69,910 | $14,906 | 21.3% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 60 | 62 | $39,606 | $6,664 | 16.8% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 37 | 58 | $16,553 | $3,834 | 23.2% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 32 | 32 | $12,572 | $2,189 | 17.4% |
| 99231 | Follow-up hospital inpatient care per day, typically 15 minutes | Facility | 2022 | 34 | 60 | $6,272 | $1,486 | 23.7% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 60 | 107 | $25,252 | $5,136 | 20.3% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 12 | 12 | $8,028 | $1,398 | 17.4% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2020 | 77 | 130 | $30,680 | $6,320 | 20.6% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2020 | 12 | 12 | $8,028 | $1,288 | 16.0% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2020 | 11 | 12 | $4,272 | $839.28 | 19.6% |
About Matt Gatlin
Matt Gatlin is a Nurse Practitioner healthcare provider based in Gulfport, Mississippi. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/15/2019. The National Provider Identifier (NPI) number assigned to this provider is 1629634506.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Matt Gatlin has received a total of $3,851 in payments from pharmaceutical and medical device companies, with $320.79 received in 2024. These payments were reported across 158 transactions from 16 companies. The most common payment nature is "Food and Beverage" ($3,518).
As a Medicare-enrolled provider, Gatlin has provided services to 1,117 Medicare beneficiaries, totaling 2,033 services with total Medicare billing of $111,073. Data is available for 4 years (2020–2023), covering 16 distinct procedure/service records.
Ad
Practice Information
- Specialty Nurse Practitioner
- Location Gulfport, MS
- Active Since 05/15/2019
- Last Updated 05/15/2019
- Taxonomy Code 363L00000X
- Entity Type Individual
- NPI Number 1629634506
Products in Payments
- XERAVA (Drug) $884.78
- NUZYRA (Drug) $364.27
- Cresemba (Drug) $331.49
- CABENUVA (Biological) $209.53
- DOVATO (Drug) $185.43
- Rezzayo (Drug) $132.89
- DIFICID (Drug) $113.85
- Kimyrsa (Drug) $105.88
- MAVYRET (Drug) $98.39
- Veklury (Drug) $79.96
- PIFELTRO (Drug) $74.94
- CRESEMBA (Drug) $74.06
- EGRIFTA (Drug) $45.29
- SYMTUZA (Drug) $44.25
- Vabomere (Drug) $41.13
- RELISTOR (Drug) $40.81
- AMBISOME (Drug) $40.04
- VIBATIV (Drug) $39.41
- AVYCAZ (Drug) $35.17
- Fetroja (Drug) $32.88
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Nurse Practitioner Doctors in Gulfport
Rebecca Ramirez, Np, NP
Nurse Practitioner — Payments: $20,807
Nurse Practitioner $20,807
Mariah Cox, Np, NP
Nurse Practitioner — Payments: $8,282
Nurse Practitioner $8,282
Jared Deloach, Np, NP
Nurse Practitioner — Payments: $4,350
Nurse Practitioner $4,350
Brenda Bennett, Cfnp, CFNP
Nurse Practitioner — Payments: $4,286
Nurse Practitioner $4,286
Mrs. Julie Ainsworth, Np, NP
Nurse Practitioner — Payments: $3,839
Nurse Practitioner $3,839
Sabrina Clark, Np, NP
Nurse Practitioner — Payments: $3,608
Nurse Practitioner $3,608